07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

Ryzodeg insulin degludec/insulin aspart regulatory update

EMA’s CHMP recommended expanding the label of Ryzodeg insulin degludec/insulin aspart from Novo Nordisk to treat Type I and Type II diabetes to include pediatric patients ages >=2. Ryzodeg is approved in adults. The product...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Clinical News

Ryzodeg insulin degludec/insulin aspart regulatory update

FDA approved NDAs from Novo Nordisk for Tresiba insulin degludec and Ryzodeg insulin degludec/insulin aspart to improve glycemic control in adult Type I and II diabetics. Novo Nordisk said Tresiba would be available to specialists...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Clinical News

Tresiba insulin degludec regulatory update

FDA approved NDAs from Novo Nordisk for Tresiba insulin degludec and Ryzodeg insulin degludec/insulin aspart to improve glycemic control in adult Type I and II diabetics. Novo Nordisk said Tresiba would be available to specialists...
07:00 , Oct 5, 2015 |  BioCentury  |  Finance

Drawn and quartered

There was no joy to be had in 3Q15, as every biotech market cap band fell by at least 15%. After the carnage only one group - companies valued north of $5 billion - are...
23:46 , Sep 25, 2015 |  BC Extra  |  Company News

FDA approves Novo's Tresiba, Ryzodeg

FDA approved both Tresiba insulin degludec and Ryzodeg insulin degludec/insulin aspart from Novo Nordisk A/S (NYSE:NVO; CSE:NVO) to improve glycemic control in adults with Types I and II diabetes. Novo spokesperson Ken Inchausti told BioCentury...
02:03 , Aug 7, 2015 |  BC Extra  |  Company News

Novo reports weakening diabetes sales in China

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) reported earnings and said China sales declined 6% in 2Q15 compared to 2Q14, as measured in local currencies. On a conference call, CEO Lars Sorensen acknowledged a decline in the...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Clinical News

Ryzodeg insulin degludec/insulin aspart regulatory update

Novo Nordisk said FDA accepted for review 2 resubmitted NDAs for Tresiba insulin degludec and Ryzodeg insulin degludec/insulin aspart to treat Type I and II diabetes. Novo Nordisk said the resubmissions would be considered a...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Clinical News

Tresiba insulin degludec regulatory update

Novo Nordisk said FDA accepted for review 2 resubmitted NDAs for Tresiba insulin degludec and Ryzodeg insulin degludec/insulin aspart to treat Type I and II diabetes. Novo Nordisk said the resubmissions would be considered a...
00:31 , Apr 8, 2015 |  BC Extra  |  Company News

FDA again reviewing Novo insulins

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) said FDA accepted for review resubmitted NDAs for Tresiba insulin degludec and Ryzodeg insulin degludec/insulin aspart to treat Type I and Type II diabetes in adults. The resubmissions of the...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Company News

Novo Nordisk sales and marketing update

Novo Nordisk launched Ryzodeg insulin degludec /insulin aspart in Mexico to treat Type II diabetes. Novo Nordisk said Mexico is the first country where Ryzodeg is available and that it plans to launch the product...